Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.63 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811077 | 0.85 | EGFR (0.73) | EGFRERBB2EPHB2ABCG2FBP1 | |
| SCHEMBL6836376 | 0.82 | EGFR (1.00) | EGFREPHB2ABCG2FBP1AURKA | |
| SCHEMBL6837272 | 0.82 | EGFR (1.00) | EGFRERBB2EPHB2ABCG2FBP1 | |
| SCHEMBL6833180 | 0.81 | EGFR (1.00) | EGFRERBB2MKNK1EPHB2ABCG2 | |
| SCHEMBL6837611 | 0.81 | EGFR (1.00) | EGFREPHB2ABCG2FBP1 | |
| SCHEMBL6837179 | 0.80 | EGFR (1.00) | EGFRERBB2MEN1KMT2ATNK2 | |
| SCHEMBL250318 | 0.78 | EGFR (1.00) | EGFRABCG2FBP1AURKAAURKB | |
| SCHEMBL6837859 | 0.78 | EGFR (1.00) | EGFRERBB2MEN1KMT2ATNK2 | |
| SCHEMBL1262166 | 0.78 | EGFR (1.00) | EGFRERBB2MEN1KMT2ATNK2 | |
| SCHEMBL2992623 | 0.72 | EGFR (1.00) | EGFRERBB2EPHB2ABCG2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713484-B2 | FUSED RING PYRIMIDINE DERIVATIVES; LOW CYTOTOXICITY | WARNER-LAMBERT COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2003-10-02 | — | — | US | disclosed |
| US-6521620-B1 | Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity | WARNER-LAMBERT COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6455534-B2 | ANTIPROLIVERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; MITOGENESIS-ACTIVATED PROTEIN KINASE INHIBITORS; NONCYTOTOXIC; BINDING WITH HIGH AFFINITY AT THE ADENOSINE TRIPHOSPHATE BINDING SITE OF THE KINASES | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885MEN1 3319/4885 |
| US-20030186987-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885MEN1 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.